Exacis is developing both NK and T cell treatments that contain genomic edits intended to decrease patients’ immune systems from recognizing and killing the cells (rejection resistance) and preventing the adopted cells from interfering with the host immune system (avoidance of graft vs. host disease). These cells are frozen and shipped for storage at point-of-care. They are administered off-the-shelf rather than requiring manufacturing on a single patient basis with the attendant costs, complexities, and timelines. Our approach includes editing components of the immune recognition system that render our products to be “stealth” cells. This avoids graft versus host attack and also increases persistence. This aspect of manufacturing, coupled with our ability to clonally generate large numbers of cells without requiring donors, supports our ability to stock our product on the shelves at multiple treating facilities.